Company intelligence / Profile preview

ANeuroTech

Ownership: Private
Development stage: Phase 3

Overview

ANeuroTech's lead compound ANT-01 has completed Phase IIIa trials and received FDA IND approval for pivotal Phase IIIB trials as an adjunctive treatment for Major Depressive Disorder. Published Phase IIIa data demonstrates a substantially better safety profile than previous serotonin and dopamine antagonists for MDD treatment.

Therapeutic areas: Psychiatry
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

ANT-01

Unknown

Partnerships

IQVIA Biotech

Beyond the preview

Go deeper on ANeuroTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANeuroTech.

Explore the full profile